Genelux Ebitda from 2010 to 2024

GNLX Stock   2.59  0.13  4.78%   
Genelux Common EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Genelux Common EBITDA regression line of annual values had significance of  0.08 and arithmetic mean of (12,208,810). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-26.5 M
Current Value
-25.1 M
Quarterly Volatility
6.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Genelux Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genelux Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 883.5 K, Interest Expense of 4.2 M or Other Operating Expenses of 16.8 M, as well as many indicators such as Price To Sales Ratio of 2.1 K, Dividend Yield of 0.0 or PTB Ratio of 18.45. Genelux financial statements analysis is a perfect complement when working with Genelux Common Valuation or Volatility modules.
  
Check out the analysis of Genelux Common Correlation against competitors.
For more information on how to buy Genelux Stock please use our How to Invest in Genelux Common guide.

Latest Genelux Common's Ebitda Growth Pattern

Below is the plot of the Ebitda of Genelux Common over the last few years. It is Genelux Common's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genelux Common's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Genelux Ebitda Regression Statistics

Arithmetic Mean(12,208,810)
Coefficient Of Variation(49.76)
Mean Deviation3,877,429
Median(10,393,000)
Standard Deviation6,074,929
Sample Variance36.9T
Range24.7M
R-Value(0.46)
Mean Square Error31.3T
R-Squared0.21
Significance0.08
Slope(625,954)
Total Sum of Squares516.7T

Genelux Ebitda History

2024-25.1 M
2023-26.5 M
2022-1.7 M
2021-14.1 M
2020-11.8 M

About Genelux Common Financial Statements

Genelux Common investors use historical fundamental indicators, such as Genelux Common's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Genelux Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-26.5 M-25.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Genelux Stock Analysis

When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.